HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: clinchem.2005.053090v1 51/10/1946    most recent Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (37) Citing Articles via Google Scholar Google Scholar Articles by Lopez, M. F. Articles by Wolfe, G. M. Search for Related Content PubMed PubMed Citation Articles by Lopez, M. F. Articles by Wolfe, G. M. Related Collections Proteomics and Protein Markers Oak Ridge Conference

High-Resolution Serum Proteomic Profiling of Alzheimer Disease Samples Reveals Disease-Specific, Carrier-Protein–Bound Mass Signatures

¹ PerkinElmer Life and Analytical Sciences, Boston, MA.
² PerkinElmer Life and Analytical Sciences, Shelton, CT.
³ Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago, IL.
⁴ PerkinElmer Life and Analytical Sciences, Beaconsfield, Bucks, United Kingdom.
⁵ Clinical Proteomics Reference Laboratory, SAIC-Frederick, Inc., NCI Frederick, Gaithersburg, MD.
⁶ Predictive Diagnostics, Inc., Vacaville, CA.

^aAddress correspondence to this author at: PerkinElmer Life and Analytical Sciences, 249 Albany St., Boston, MA 02118. Fax 617-350-9658; e-mail mary.lopez{at}perkinelmer.com.

Abstract

Background: Researchers typically search for disease markers using a "targeted" approach in which a hypothesis about the disease mechanism is tested and experimental results either confirm or disprove the involvement of a particular gene or protein in the disease. Recently, there has been interest in developing disease diagnostics based on unbiased quantification of differences in global patterns of protein and peptide masses, typically in blood from individuals with and without disease. We combined a suite of methods and technologies, including novel sample preparation based on carrier-protein capture and biomarker enrichment, high-resolution mass spectrometry, a unique cohort of well-characterized persons with and without Alzheimer disease (AD), and powerful bioinformatic analysis, that add statistical and procedural robustness to biomarker discovery from blood.

Methods: Carrier-protein–bound peptides were isolated from serum samples by affinity chromatography, and peptide mass spectra were acquired by a matrix-assisted laser desorption/ionization (MALDI) orthogonal time-of-flight (O-TOF) mass spectrometer capable of collecting data over a broad mass range (100 to >300 000 Da) in a single acquisition. Discriminatory analysis of mass spectra was used to process and analyze the raw mass spectral data.

Results: Coupled with the biomarker enrichment protocol, the high-resolution MALDI O-TOF mass spectra provided informative, reproducible peptide signatures. The raw mass spectra were analyzed and used to build discriminant disease models that were challenged with blinded samples for classification.

Conclusions: Carrier-protein enrichment of disease biomarkers coupled with high-resolution mass spectrometry and discriminant pattern analysis is a powerful technology for diagnostics and population screening. The mass fingerprint model successfully classified blinded AD patient and control samples with high sensitivity and specificity.

The following articles in journals at HighWire Press have cited this article:

				E. P. Diamandis Oncopeptidomics: A Useful Approach for Cancer Diagnosis? Clin. Chem., June 1, 2007; 53(6): 1004 - 1006. [Full Text] [PDF]

				M. F. Lopez, A. Mikulskis, S. Kuzdzal, E. Golenko, E. F. Petricoin III, L. A. Liotta, W. F. Patton, G. R. Whiteley, K. Rosenblatt, P. Gurnani, et al. A Novel, High-Throughput Workflow for Discovery and Identification of Serum Carrier Protein-Bound Peptide Biomarker Candidates in Ovarian Cancer Samples Clin. Chem., June 1, 2007; 53(6): 1067 - 1074. [Abstract] [Full Text] [PDF]

				J. Albrethsen Reproducibility in Protein Profiling by MALDI-TOF Mass Spectrometry Clin. Chem., May 1, 2007; 53(5): 852 - 858. [Abstract] [Full Text] [PDF]

				A. Hye, S. Lynham, M. Thambisetty, M. Causevic, J. Campbell, H. L. Byers, C. Hooper, F. Rijsdijk, S. J. Tabrizi, S. Banner, et al. Proteome-based plasma biomarkers for Alzheimer's disease. Brain, November 1, 2006; 129(Pt 11): 3042 - 3050. [Abstract] [Full Text] [PDF]

				G. L. Hortin The MALDI-TOF Mass Spectrometric View of the Plasma Proteome and Peptidome Clin. Chem., July 1, 2006; 52(7): 1223 - 1237. [Abstract] [Full Text] [PDF]

				G. L. Hortin, S. A. Jortani, J. C. Ritchie Jr, R. Valdes Jr, and D. W. Chan Proteomics: A New Diagnostic Frontier Clin. Chem., July 1, 2006; 52(7): 1218 - 1222. [Abstract] [Full Text] [PDF]

				P. Kepper, R. Reinhardt, A. Dahl, H. Lehrach, and S. Sauer Matrix-Assisted Laser Desorption/Ionization Mass Spectrometric Analysis of DNA on Microarrays Clin. Chem., July 1, 2006; 52(7): 1303 - 1310. [Abstract] [Full Text] [PDF]